What Axon Therapies does

Axon Therapies, Inc. (a trade name of parent Axon Vascular, Inc.) is a private, New York-based medtech company developing the SAVM (Splanchnic Ablation for Volume Management) procedure and its proprietary Satera Ablation System for treating heart failure, with a primary focus on patients with preserved ejection fraction (HFpEF). The SAVM procedure is a minimally invasive, implant-free, catheter-based intervention that unilaterally ablates the right greater splanchnic nerve to reduce sympathetic nervous system overactivity and normalize pathological volume redistribution from the splanchnic bed back to the heart, addressing a root cause of heart failure rather than symptom management alone. The Satera Ablation System consists of a small 7F over-the-wire irrigated RF catheter delivered via the femoral vein and navigated to the target vessel; the procedure is designed as an outpatient intervention lasting under an hour with same-day discharge.

The company is led by CEO Chad Hoskins (formerly GM Heart Failure at Abbott and McKinsey medtech consultant), co-founder/CMO Howard Levin, MD (heart failure cardiologist and multiple medtech exit originator via Coridea), COO PJ Iranitalab (ex-Apama Medical/Boston Scientific, St. Jude EP), and SVP Clinical & Regulatory Matthew Stark, PhD, MBA. Capital structure includes a $32 million oversubscribed Series A closed in September 2025 led by Earlybird Venture Capital and Santé Ventures, alongside prior backers Deerfield Management, Action Potential Venture Capital (GSK's CVC), Coridea (founding incubator), CD Capital, and Kofa Healthcare. IP coverage spans at least seven issued US patents on the SAVM method and catheter, plus registered Axon™ and Satera™ trademarks. Clinical momentum is anchored by the REBALANCE-HF IDE Feasibility Trial (NCT04592445), with 12-month responder cohort data presented at THT 2025 showing -18 mmHg exercise PCWP, +17 KCCQ quality-of-life points, and +49 meters on 6-minute walk distance versus sham.

Commercially, Axon is pre-revenue: the Satera Ablation System is investigational and not approved for clinical use in any geography, with revenue model limited to future hardware (and related disposables) sales to hospital catheterization labs and electrophysiology departments post-approval, distributed via direct enterprise field sales. The company is building global readiness with a US headquarters in New York and a European headquarters in Altrincham, UK (Axon Vascular Europe Limited). Target customers are HFpEF patients (approximately 50% of the ~6 million US heart failure population) who today face limited treatment options and a roughly 50% five-year mortality rate; pricing and contract structures are not publicly disclosed.

Name

Axon Therapies

Legal name

Axon Therapies, Inc.

Website

https://axontherapies.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

Axon Therapies is a private New York-based medtech company developing the Satera Ablation System, a catheter-based neuromodulation platform that ablates the right greater splanchnic nerve to treat heart failure, primarily targeting HFpEF patients via the investigational SAVM procedure.

Ownership category

akta.pro rank

Product category

Cardiac Neuromodulation Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation) (HLAHAFAL)

akta.pro secondary industries

Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS) (HLAHAEAK), Electrophysiology Mapping & Ablation Systems (HLAHAFAD)

Keywords

• Cardiac neuromodulation therapy
• Catheter ablation devices
• Heart failure treatment
• Splanchnic nerve ablation
• Minimally invasive cardiology

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Medical Device Sales (Hardware): Once regulatory approval is obtained, Axon Therapies will generate revenue through the sale of the Satera Ablation System and related disposable catheters to hospitals and clinical facilities performing the SAVM procedure. The company is currently in clinical trial stage with an investigational device not yet approved for commercial use.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Axon Therapies develops the Satera Ablation System, an investigational catheter-based device used to perform the SAVM (Splanchnic Ablation for Volume Management) procedure, a minimally invasive, implant-free therapy that ablates the right greater splanchnic nerve to reduce sympathetic nervous system overactivity and address volume redistribution in heart failure patients with preserved ejection fraction (HFpEF). The system consists of a small 7F catheter delivered over the wire through the femoral vein, with irrigation during energy delivery for consistent heat transfer and lesion development. The outpatient procedure is typically completed in under an hour with same-day discharge capability.

Product overview

Axon Therapies offers a unified medical technology solution consisting of the SAVM (Splanchnic Ablation for Volume Management) procedure and the Satera Ablation System. The Satera Ablation System is the catheter-based hardware used to perform the SAVM procedure, which is an investigational treatment targeting the sympathetic nervous system to address volume redistribution issues in heart failure patients with preserved ejection fraction (HFpEF). The procedure is minimally invasive, implant-free, and typically takes under an hour with same-day discharge capability.

Differentiator

Problem solved

Functional benefit

Products and services

• Satera Ablation System An investigational catheter-based ablation system used to perform the SAVM (Splanchnic Ablation for Volume Management) procedure. The system includes a small 7F ablation catheter inserted through the femoral vein and navigated to a target vessel near the right greater splanchnic nerve, with irrigation during energy delivery to support consistent heat transfer and lesion development. The procedure is implant-free, minimally invasive, and typically performed in under an hour with same-day discharge capability, intended for interventional cardiologists and electrophysiologists treating HFpEF patients in hospital catheterization labs.
• SAVM Procedure (Splanchnic Ablation for Volume Management) A minimally invasive, implant-free catheter procedure that unilaterally ablates the right greater splanchnic nerve to calm sympathetic activity with the goal of normalizing volume balance, increasing cardiac functional capacity, and improving symptoms for heart failure patients with preserved ejection fraction (HFpEF). Performed in hospital catheterization labs by interventional cardiologists and electrophysiologists on an outpatient basis.

Quantifiable outcome

• Reduced peak PCWP by 18 mmHg vs. sham at 12 months
• +3 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Corideafounding partnerStrategic or Co-development PartnerMedical device incubator that founded Axon Therapies. Co-founded by Howard Levin, MD, who has successfully launched multiple medtech companies including Ardian (Medtronic), CHF Solutions, Respicardia, and others through Coridea.

Scale indicators1 record

Recent moves7 records

Expansion highlights6 records

Direct peers

• CVRx: CVRx develops the Barostim neo system, an implantable neuromodulation device for heart failure — the most direct competitor to Axon in nerve-modulation therapy for HF, targeting a similar unmet need in HFrEF (and exploring HFpEF).
• Respicardia: A Coridea spinout (same incubator as Axon) developing the remede System, an implantable neurostimulation device for central sleep apnea in heart failure patients — same DNA, same sympathetic/CV neuromodulation focus.
• Recor Medical: Recor is developing the Paradise renal denervation system, a catheter-based ultrasound ablation therapy for hypertension — a closely analogous catheter-ablation neuromodulation approach for sympathetic-overactivity cardiovascular disease.

Broad incumbents

• Medtronic: Medtronic acquired Ardian (renal denervation) from Coridea and continues to develop the Symplicity Spyral renal denervation program; it is the most likely strategic acquirer of Axon and a broad incumbent across HF devices, ablation, and neuromodulation.
• Boston Scientific: Boston Scientific is a dominant player in cardiac electrophysiology and ablation catheters, and previously acquired Apama Medical where Axon's COO PJ Iranitalab was VP of R&D — a natural incumbent acquirer for catheter-based ablation IP.
• Edwards Lifesciences: Edwards is the leading structural heart device company and has been moving into heart failure management; a broad incumbent that could partner with or compete against Axon in catheter-based heart-failure interventions.

Others

• Abbott: Abbott markets the CardioMEMS HF System, HeartMate left ventricular assist devices, and the CentriMag family; it is a major HF device incumbent and a potential acquirer given Chad Hoskins's prior leadership of Abbott's Heart Failure Therapies franchise.
• Reprieve Cardiovascular: Reprieve Cardiovascular (formerly RenalGuard Solutions) is another Coridea spinout developing fluid-management therapy for acute decompensated heart failure — a sibling portfolio company sharing the same incubator IP and approach to volume management in HF.

Emerging players

• Axonics: Axonics develops sacral and pudendal neuromodulation systems for incontinence — a peer emerging neuromodulation device company with a comparable miniaturized, implant-based platform and similar growth-stage commercial trajectory.
• Inspire Medical Systems: Inspire markets an implantable hypoglossal nerve stimulation system for obstructive sleep apnea, demonstrating the commercial viability of nerve-targeted stimulation devices and serving as a comparable neuromodulation medtech business model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/axon-therapies-inc.

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries1 record

Funding overview

Funding rounds4 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Axon Therapies